3Ominsky MS, Kostenuik PJ, Cranmer P, et al. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonadintact cynomolgus monkeys[J]. Osteoporos Int, 2007, 18(8) : 1073- 1082.
4Ominsky MS, Li X, Asuncion FJ, et al, RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats [ J ]. J Bone Miner Res, 2008, 23 (5) : 672 - 682.
5Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women [ J ]. J Bone Miner Res, 2001, 16(2): 348 - 360.
6Body JJ, Greipp P, Coleman RE, et al. A phase Ⅰ study of AMGN- 007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [ J ]. Cancer, 2003, 97 ( Suppl 3 ) : 887 - 892.
7Smith BB, Cosenza ME, Mancini A, et al. A toxicity profile of osteoprotegerin in the cynomolgus monkey[J].Int J Toxicol, 2003, 22 (5) : 403 -412.
8斯佩克特(黄培堂,等译).组织培养技术[M].北京:科学出版社,2001:576-581.
9Onet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[ J ]. Cell, 1997, 89(2) : 309 -319.
